

1 Blood transfusion in care of patients with Visceral Leishmaniasis: a review
2 of practices in therapeutic efficacy studies

3 Prabin Dahal*^{1,2}, Sauman Singh-Phulgenda^{1,2}, James Wilson^{1,2}, Glauca Cota³, Koert
4 Ritmeijer⁴, Ahmed Musa⁵, Fabiana Alves⁶, Kasia Stepniewska^{1,2}, Philippe J Guerin*^{1,2}

5

6 ¹Infectious Diseases Data Observatory (IDDO), Oxford, UK

7 ²Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
8 University of Oxford, Oxford, UK

9 ³Instituto René Rachou (IRR), Fiocruz, Minas Gerais, Brazil

10 ⁴Médecins Sans Frontières, Amsterdam, Netherlands

11 ⁵Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan

12 ⁶Drugs for Neglected Diseases initiative, Geneva, Switzerland

13

14

15

16 **Keywords:** Kala azar; visceral leishmaniasis; transfusion; anaemia; haemoglobin

17

18

19 ***Correspondence:** prabin.dahal@ndm.ox.ac.uk; philippe.guerin@ndm.ox.ac.uk

20 **Abstract**

21 Anaemia is a common presentation feature in patients with visceral leishmaniasis (VL).
22 Blood transfusion remains an important aspect of patient management in VL. However,
23 triggers considered for making decisions on transfusion are poorly understood. This review
24 is based on the Infectious Diseases Data Observatory (IDDO) VL clinical trials library, a
25 database of all published efficacy studies since 1980 and has indexed 160 published trials
26 (1980–2021). Description of blood transfusion was reported in 16 (10.1%) trials (n=3,459
27 patients). Transfusion was initiated solely based on haemoglobin (Hb) measurement in 9
28 studies, using a combination of Hb and other health conditions (epistaxis, poor health, or
29 clinical instability) in 3 studies, and the criteria was unclear in 4 studies; Hb threshold ranged
30 from 3-8 g/dL. Overall, the number of patients receiving transfusion was explicitly reported
31 in 10 trials (n=2,421 patients enrolled). Of these, 217 patients underwent transfusion; 58
32 before treatment initiation and 46 during treatment or the follow-up phase, and the time of
33 transfusion was unclear in 113. The median proportion of patients who received a
34 transfusion in a study was 8.0% [Interquartile range (IQR): 4.7% to 47.2%; range: 0-100%;
35 n=10 studies]. This review describes the variation in current clinical practice and is an
36 important initial step in policy/guideline development, where both the patient's
37 haemoglobin concentration and clinical status must be considered.

38 **Word count:** abstract (n=219 words); main text (n = 2713 words)

39 Introduction

40 Visceral leishmaniasis (VL) is the most severe of the three forms of leishmaniasis and,
41 is fatal without treatment. The disease typically presents insidiously and is characterised by
42 protracted fever, hepatosplenomegaly and weight loss, often with evolving anaemia,
43 leukopaenia and thrombocytopaenia leading to pancytopaenia.¹ At presentation, moderate
44 anaemia around 7–10 g/dL is common but can evolve into severe anaemia.¹ While the
45 underlying mechanism for the onset of anaemia in VL is likely multifactorial, the literature
46 suggests the main cause is due to macrophage induced haemolysis in the spleen (“splenic
47 sequestration, splenic haemophagocytosis”).²

48 The WHO defines anaemia based on the haemoglobin levels below the reference
49 values based on age, sex, and pregnancy status.³ In patients presenting with severe
50 anaemia, especially when accompanied by signs of anaemia (typically shortness of breath,
51 fatigue, weakness, light-headedness, occasionally chest pain), transfusion of blood products
52 may be therefore clinically indicated. Red blood cell (RBC) transfusion may also be indicated
53 in cases of acute blood loss due to invasive procedures such as splenic aspiration or venous
54 catheterisation or due to spontaneous haemorrhage from a VL-related bleeding diathesis.
55 Bleeding risk is exacerbated in VL patients as the disease can lead to alterations of hepatic
56 coagulation factors and thrombocytopaenia.⁴ Therefore, operational manuals from national
57 control programmes suggest that haematological factors are taken into consideration prior
58 to splenic aspirations (or completely contra-indicate splenic aspiration) and that blood
59 transfusion services are in place for the management of acute blood loss.^{4–8}

60 Despite a clear recognition of the importance of transfusion in the management of
61 VL patients, the actual transfusion practice in clinical trials or daily management of patients

62 is poorly documented. In this review, we aim to collate information on blood transfusion
63 among VL patients enrolled in therapeutic efficacy trials.

64 **Methodology**

65 **Information sources and search strategy for clinical trials**

66 This review synthesises data from studies indexed in the Infectious Diseases Data
67 Observatory (IDDO) VL clinical trials library of prospective therapeutic studies from 1980
68 until Nov-2021⁹; details of the search strategy adopted for each of the databases have been
69 described elsewhere.¹⁰ Data on the following aspects of design and conduct of studies
70 captured by the IDDO VL library were extracted: the number of participants enrolled, details
71 on the timing of transfusion (baseline, during treatment phase, or during the follow-up
72 phase after discharge), and the details of the blood products transfused (whole blood,
73 packed red blood cells (PRBC), plasma, or platelets), the haemoglobin threshold used for
74 patient inclusion, and the transfusion triggers adopted.

75 **Data summary and analysis**

76 A descriptive summary of the data extracted is presented. The median proportion of
77 patients reported to have received blood products is presented along with the range and
78 inter-quartile range. No formal meta-analysis was undertaken owing to the large
79 heterogeneity in transfusion practices adopted. All statistical analyses were carried out
80 using R software.¹¹

81 **Risk of bias assessment**

82 The risk of bias assessment in studies included in this review was carried out using
83 the Cochrane Risk of Bias (ROB) tool for randomised controlled trials.¹² Risk of bias in non-
84 randomised studies will be carried out using ROBINS-I tool.¹³ Two reviewers (PD and SS)
85 independently assessed the risk of bias.

86 Results

87 The IDDO systematic review library has currently indexed 160 publications (35,763
88 patients; 1980–2021). There were 108 (67.5%) studies from the Indian subcontinent, 27
89 (16.9%) from East Africa, 9 (5.6%) from the Mediterranean region, 7 (4.4%) from South
90 America, 5 (3.1%) from Central Asia (the Middle East), and 4 (2.5%) were multi-regional
91 studies. The haematological measures adopted for patient inclusion are presented in **Table**
92 **1**. The minimum haemoglobin concentration required for inclusion was 3 g/dL in 8 (5.0%)
93 studies, >3-5 g/dL in 38 (23.8%) studies, >5-7 g/dL in 22 (13.8%) studies, and unclear in the
94 remaining 92 (57.5%) studies. Ranges of other haematological parameters considered at
95 inclusion are presented in **Table 1**.

96 Transfused products and transfusion triggers (n=16 studies)

97 Of the 160 studies in the IDDO VL systematic review library, the description of blood
98 transfusion was explicitly reported in 16 (10.1%) studies (n=3,459 patients; 1984-
99 2018)(**Table 2**). 7/108 studies from the Indian sub-continent, 6/27 studies from East Africa,
100 2/7 studies from South America, 1/5 studies from Central Asia and none of the 9 studies
101 from the Mediteeranean region or none of the 4 multi-regional studies reported data on
102 blood transfusion. Patients living with VL-HIV co-infection were included in 2 studies (n=113
103 patients), excluded in 4 studies (n=384 patients), and unclear in the remaining 10 studies
104 (n=2,962 patients). Pregnant women were included in 3 studies (n=996 patients), excluded
105 in 4 studies (n=304 patients), and unclear in the remaining 9 studies (n=2,159 patients).

106 Transfusion was not required for any patient in 1 study, and in the remaining 15
107 studies, transfusion of either whole blood or other blood products was reported (**Table 2**).
108 Transfusion of blood (without specifying if whole blood was transfused or the blood

109 components) was reported in 12 studies, 1 study transfused red blood cells, and 2 studies
110 reported transfusing either blood (without making distinction if whole blood or packed RBC)
111 or platelets.

112 Transfusion was initiated solely based on the measured concentration of
113 haemoglobin (or anaemia status) or platelet concentrations in 9 studies (**Table 2**). In 2
114 studies from India, the transfusion trigger was a combination of measured haemoglobin
115 concentration and existing of clinical conditions such as epistaxis or poor health ^{14,15}. In a
116 study from Brazil ¹⁶, the measured concentration of red cells or international normalisation
117 ratio (INR) in addition to the clinical condition of the patient was adopted; transfusion of
118 RBC was undertaken if a patient had severe anaemia (haemoglobin <8 g/dL) along with
119 clinical instability and plasma transfusion was undertaken if the INR >1.5 and the patient
120 had active bleeding. The criteria used for blood transfusion were not stated in the remaining
121 4 studies (**Table 2**). The haemoglobin threshold used as a transfusion trigger was 3 g/dL in 2
122 studies, 4 g/dL in 2 studies, 5 g/dL in 2 studies, 6 g/dL in 1 study, 8 g/dL in 1 study, anaemia
123 or severe anaemia status (without reporting the haemoglobin threshold) in 3 studies, and
124 the threshold was not clear in 1 study.

125 Of the 2 studies that reported on platelet transfusion, a threshold of <65,000 cells/ μ L
126 was used in a study from India ¹⁷, and in another study from Brazil [14], a threshold of
127 <50,000 cells/ μ L was adopted among those who were given prophylactic transfusion before
128 undertaking invasive procedures and a threshold of <20,000 cells/ μ L for patients with active
129 bleeding (**Table 2**).

130 **The number of blood transfusions reported (n=10 studies)**

131 The number of patients who received transfusions were clearly reported in only 10
132 trials (2,421 patients enrolled); a total of 217 patients received blood transfusions (total
133 number of transfusion episodes were not reported). Of these 217 patients, 58 transfusions
134 occurred before initiation of antileishmanial therapies^{15,18}, 46 patients underwent
135 transfusion during treatment or follow-up phase¹⁸⁻²⁰, and the time when transfusion was
136 carried out was not reported for the remaining 113 patients (**Table 2**). Overall, from the 10
137 studies that clearly reported transfusion data, the median proportion of patients who
138 received a transfusion at any time-point in the study was 8.0% [Interquartile range (IQR):
139 4.7% to 47.2%; range: 0-100%] (**Figure 1**).

140 Two studies described transfusion among pregnant women: in a patient (1/16) in a
141 study from Kenya (transfused at 3.2 g/dL)²¹ and all patients (100%, 42/42) in another study
142 on VL in pregnant women from Sudan (transfusion based on severe anaemia)²². In 3 studies
143 that explicitly enrolled children <15 years, of the 112 enrolled, 29 required transfusions
144 (**Table 2 and supplemental table 1**); the criteria for transfusion was Hb concentration <4
145 g/dL along pre-existing hemorrhagic problems in a study from India²³ and this unclear in
146 studies from Yemen²⁴ and East Africa²⁰.

147 Two studies enrolled patients with HIV co-infections; 23/44 (52.2%) patients from a
148 study in Brazil¹⁶ required transfusion; and the actual number of patients requiring
149 transfusion was not reported in a study from Ethiopia (n=23 enrolled; number requiring
150 transfusions was not reported)²⁵.

151 **Risk of bias assessment in studies included**

152 Of the 16 studies included, 4 were randomised, and 12 were non-randomised
153 studies. The four randomised studies were judged to be at high/unclear risk of bias on
154 blinding domain, low or unclear risk of bias on sequence generation and allocation conceal
155 domain. Of the 12 non-randomised studies, all of them were either open label or this
156 description was unclear, bias in participants selection was considered low/moderate in 10
157 studies, high in 1 study, and unclear in 1 study. Risk of bias assessment is presented in
158 **supplemental file 1.**

159 Discussion

160 From the studies indexed in the IDDO VL clinical trials library, reporting of
161 information on blood transfusion was not explicit in the majority of clinical trials. These
162 could be partly due to the exclusion of patients with severe anaemia or severe disease in
163 standard efficacy studies in VL. For example, approximately 40% of the 160 therapeutic
164 efficacy studies excluded patients with haemoglobin concentrations less than 5 g/dL. The
165 combination of inclusion/exclusion criteria adopted will likely lead to the exclusion of severe
166 patients who may be less likely to require transfusion. From the 16 studies that clearly
167 reported occurrences (or absences) of blood transfusion, the criteria adopted for
168 transfusion varied between the studies. Most of the studies reported initiating blood
169 transfusion based on thresholds of haemoglobin concentration or anaemia status, without
170 taking other factors (for example, clinical stability/bleeding conditions/poor health) into
171 consideration; the haemoglobin concentration used as a transfusion trigger ranged from 3-8
172 g/dL. This wide variation is particularly relevant as recent studies (non-VL context) have
173 pointed towards the lack of benefit of blood transfusion in preventing mortality when
174 transfusion is initiated at haemoglobin concentration greater than 4 g/dL.²⁶⁻²⁹ Such
175 assessment of the risk-benefit ratio associated with transfusion was not possible in this
176 review as clinical outcomes were not disaggregated by transfusion status in the included
177 studies. In addition to these criteria, it is also important to consider further haemodynamic
178 stability and clinical history of patients, such as heart conditions, when considering the
179 adoption of a transfusion threshold.³⁰

180 The current WHO guidelines on the management of paediatric anaemia recommend
181 carrying out transfusion when haemoglobin concentration is below 4 g/dL, and among those

182 with non-severe anaemia (haemoglobin 4-6 g/dL), transfusion is only indicated if the child
183 presents with other clinical features including dehydration and heart failure.³¹ For adults,
184 specific guidelines among critically ill patients in the ICU have advocated a threshold of 7
185 g/dL and have recommended further personalising the transfusion decision based on the
186 clinical condition of the patient.³² However, only three studies included in this review
187 reported carrying out transfusion using a combination of haemoglobin concentration and
188 further clinical criteria such as clinical stability, poor health or active bleeding, such as
189 epistaxis (**Table 1**). This is particularly relevant as the ability to tolerate anaemia can partly
190 depend on the speed of its evolution, as compensatory mechanisms can enable relatively
191 severe degrees of anaemia to be tolerated if it develops over a prolonged duration.³³ VL
192 primarily affects the poor and marginalised populations with limited access to healthcare,
193 leading to a prolonged duration of illness prior to presentation. As the disease itself often
194 evolves insidiously over weeks or months, and patients often receive care late in the disease
195 course, anaemia evolves over a prolonged.³⁴ Therefore, in VL patients, it can be anticipated
196 that compensatory mechanisms will have led to a physiological adaptation to anaemia.
197 However, acute anaemia arising as a result of acute bleeding occurring due to complications
198 during splenic puncture or post-partum haemorrhage among pregnant VL patients³⁵ can
199 overwhelm the compensatory mechanisms of the body and can be fatal, thus requiring
200 immediate transfusion.

201 Further caution is urged when transfusing patients who present with severe acute
202 malnutrition (a common feature of VL patients), as fluid overload and respiratory
203 impairment are a recognised and feared complication in patients with hypoalbuminemia.³¹
204 In the studies included in this review, one case of transfusion reaction was reported²⁰; but
205 specific details on the nature of this adverse event were not presented. In other studies

206 included in this review, no reports on the occurrence of transfusion reactions or transfusion-
207 associated risks were reported. However, the absence of reporting of such occurrences
208 cannot be taken as evidence of absence of adverse events. In general, transfusion reactions
209 are estimated to occur up to 1 per 100 transfusions.³⁶ There are no such estimates specific
210 to the VL context, and the risks associated with transfusion in the context of VL are not well
211 understood.

212 From the relatively limited set of studies that reported the occurrences of
213 transfusions, the median proportion of patients who received blood transfusions was 8%
214 (n=10 studies). As mentioned earlier, patients with severe anaemia or those with severe VL
215 and pre-existing co-morbidities are excluded in standard therapeutic efficacy studies leading
216 to the inclusion of mostly uncomplicated VL cases. Therefore, the incidence of transfusion in
217 routine clinical practice is likely to be much higher. This suggests that there might be a
218 substantial economic/logistic cost to the healthcare facilities arising from the requirement
219 of transfusion in the management of VL patients. The cost could also be further increased as
220 a central cause of anaemia may require multiple transfusions leading to increased
221 expenditure and the management of potential safety risks associated with transfusion alone
222 ³⁷⁻³⁹, while the benefit for the patients may not be warranted.

223 There are several limitations with this review. Of the 160 clinical studies in the VL
224 IDDO systematic review library, the majority of the studies didn't report any transfusion
225 related data. Data on the number of transfusions carried out were also not reported;
226 therefore, the actual number of transfusion episodes remains unclear. Overall, these
227 indicate generally high or unclear risk of bias in the studies included with respect to
228 assessing blood transfusion and their effect on treatment. However, since blood transfusion

229 isn't the main focus of the efficacy studies, lack of details regarding transfusion and
230 outcomes prevented a thorough assessment of risk of bias. Instead, the overall quality of
231 studies were assessed using standard risk of bias tools. Another aspect to be considered is
232 the influence of the conditions of the health services where the patients gathered here were
233 originally treated, including the possibility of different local guidelines for transfusions. For
234 example, three studies reported undertaking haematological profile correction prior to
235 enrolment of patients without describing if any transfusions were carried out.^{15,40,41} Such
236 practice can affect the requirement for transfusion during the study. Similarly, access to
237 blood products is relatively difficult in some countries, which may have contributed to the
238 observed differences in the rate of transfusions between studies. Finally, from the reports
239 included in this review, it was not possible to reliably assess if some patient groups were
240 more or less likely to require transfusion than others; this would require an individual
241 participant data meta-analysis.

242 A checklist of items for reporting data related to transfusion is proposed in Box 1.
243 Adoption of such a checklist can facilitate better reporting of the transfusion-related
244 parameters and can enable a thorough assessment of the risks and benefits of transfusion
245 strategies adopted among VL patients in the future. Additionally, the standardisation and
246 completeness of haematological data in VL studies before, during and after treatment,
247 including information concerning blood transfusions, therapy and clinical outcome
248 stratification, may also help in recognising the dynamics of VL clinical improvement after
249 treatment, over time, contributing to the establishment of operational definitions to
250 support cure assessment.

251 **Conclusions**

252 Data regarding blood transfusions remain largely unreported in therapeutic efficacy
253 studies on VL, with information available only on 16 therapeutic efficacy studies published
254 since 1980. When reported, the decision to undertake transfusion was often found to be
255 solely based on the haemoglobin concentration of the patients, with only three studies
256 incorporating additional clinical criteria. Overall, this review represents the initial step in
257 acknowledging the magnitude of the gap related to blood derivatives use and points to the
258 need for harmonisation of the clinical data presentation in VL prospective studies. The
259 research community should adopt a standardised method for the reporting of transfusion
260 episodes so that the true benefit of transfusion in VL case management can be reliably
261 assessed.

262

263 **Authors' contributions**

264 Study Conception: PD, SSP, KS, PJG

265 Methodology: PD, SSP

266 Data curation: PD, SSP

267 Project supervision: SSP, KS, PJG

268 Project administration: PD, SSP

269 Funding acquisition: PJG

270 Writing-original draft: PD, SSP, JW, GC, KR, AM, FA, KS, PJG

271 Writing- review and editing: All authors were involved in reading and critical revision of the
272 initial draft and approved the final manuscript.

273

274 **Funding**

275 This work is funded by a Bill & Melinda Gates Foundation grant to the Infectious Diseases

276 Data Observatory, Oxford University, UK (Recipient: Prof. Philippe Guerin; ref: INV-004713).

277 Funding agency had no role in developing the manuscript or its publication.

278

279 **Conflict of Interest**

280 None

281

282 **Data Availability**

283 All the data used in this review are available within supplemental file 1.

284

285

286

287 **References**

- 288 1. Boelaert M, Sundar S. 47. Leishmaniasis. In: Jeremy Farrar, Peter Hotez, Thomas
289 Junghanss, Gagandeep Kang, David Lalloo and NJW, ed. *Manson's Tropical Diseases*.
290 Elsevier Health Sciences; 2014:631-651.
- 291 2. Goto Y, Cheng J, Omachi S, Morimoto A. Prevalence, severity, and pathogenesis of
292 anemia in visceral leishmaniasis. *Parasitol Res.* 2017;116(2):457-464.
293 doi:10.1007/s00436-016-5313-x
- 294 3. Vitamin and Mineral Nutrition Information System. World Health Organization.
295 Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity.
296 Geneva, Switzerland, World Health Organization (WHO/NMH/NHD/MNM/11.1).
297 doi:2011
- 298 4. WHO. Guideline for diagnosis, treatment & prevention of leishmaniasis in Ethiopia.
299 WHO. Published 2013. Accessed July 28, 2021.
300 [https://www.who.int/leishmaniasis/burden/Guideline_for_diagnosis_treatment_and](https://www.who.int/leishmaniasis/burden/Guideline_for_diagnosis_treatment_and_prevention_of_leishmaniasis_in_Ethiopia.pdf)
301 [_prevention_of_leishmaniasis_in_Ethiopia.pdf](https://www.who.int/leishmaniasis/burden/Guideline_for_diagnosis_treatment_and_prevention_of_leishmaniasis_in_Ethiopia.pdf)
- 302 5. Federal Ministry of Health - Republic of Sudan. Manual for the diagnosis and
303 treatment of leishmaniasis. WHO. Published 2014. Accessed July 28, 2021.
304 [https://www.who.int/leishmaniasis/burden/Manual_for_the_diagnosis_and_treatme](https://www.who.int/leishmaniasis/burden/Manual_for_the_diagnosis_and_treatment_Leishmaniasis_Guideline_Sudan_2014.pdf?ua=1)
305 [nt_Leishmaniasis_Guideline_Sudan_2014.pdf?ua=1](https://www.who.int/leishmaniasis/burden/Manual_for_the_diagnosis_and_treatment_Leishmaniasis_Guideline_Sudan_2014.pdf?ua=1)
- 306 6. National Vector Borne Disease Control Programme. Operational guidelines on kala-
307 azar (visceral leishmaniasis) elimination in India - 2015. WHO. Published 2015.
308 Accessed October 29, 2019.

- 309 [https://www.who.int/leishmaniasis/burden/Operational_guidelines_on_kala_azar_el](https://www.who.int/leishmaniasis/burden/Operational_guidelines_on_kala_azar_elimination_in_India.pdf)
310 [mination_in_India.pdf](https://www.who.int/leishmaniasis/burden/Operational_guidelines_on_kala_azar_elimination_in_India.pdf)
- 311 7. Ministry of Health R of K. Prevention, diagnosis and treatment of Visceral
312 Leishmaniasis (Kala-Azar) in Kenya. Published 2017. Accessed August 30, 2019.
313 https://www.who.int/leishmaniasis/burden/Kala_Azar_Kenya_2017.pdf?ua=1
- 314 8. Ministry of Health - Somali Fedral Government. Guidelines for diagnosis , treatment
315 and prevention of visceral leishmaniasis in Somalia. WHO. Published 2012. Accessed
316 July 28, 2021.
317 [https://www.who.int/leishmaniasis/burden/Guidelines_for_diagnosis_treatment_an](https://www.who.int/leishmaniasis/burden/Guidelines_for_diagnosis_treatment_and_prevention_of_VL_in_Somalia.pdf)
318 [d_prevention_of_VL_in_Somalia.pdf](https://www.who.int/leishmaniasis/burden/Guidelines_for_diagnosis_treatment_and_prevention_of_VL_in_Somalia.pdf)
- 319 9. Infectious Diseases Data Observatory. VL Surveyor. Published 2023. Accessed January
320 9, 2023. <https://www.iddo.org/vlSurveyor/#0>
- 321 10. Bush JT, Wasunna M, Alves F, et al. Systematic review of clinical trials assessing the
322 therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the
323 feasibility of establishing an individual patient data sharing platform. *PLoS Negl Trop*
324 *Dis.* 2017;11(9):1-16. doi:10.1371/journal.pntd.0005781
- 325 11. R Core Team. R: A language and environment for statistical computing. *R Found Stat*
326 *Comput Vienna, Austria*. Published online 2018.
- 327 12. Sterne JAC, Savović J, Page MJ, et al. RoB 2: A revised tool for assessing risk of bias in
328 randomised trials. *BMJ.* 2019;366(14898):1-8. doi:10.1136/bmj.l4898
- 329 13. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: A tool for assessing risk of bias in
330 non-randomised studies of interventions. *BMJ.* 2016;355:4-10. doi:10.1136/bmj.i4919

- 331 14. Thakur CP. Epidemiological, clinical and therapeutic features of Bihar kala-azar
332 (including post kala-azar dermal leishmaniasis). *Trans R Soc Trop Med Hyg.*
333 1984;78(3):391-398. doi:10.1016/0035-9203(84)90131-7
- 334 15. Thakur CP, Sinha GP, Pandey AK, Barat D, Sinha PK. Amphotericin B in resistant kala-
335 azar in Bihar. *Natl Med J India.* 1993;6(2):57-60.
- 336 16. Cota GF, de Sousa MR, de Mendonça ALP, et al. Leishmania-HIV Co-infection: Clinical
337 Presentation and Outcomes in an Urban Area in Brazil. *PLoS Negl Trop Dis.*
338 2014;8(4):2-8. doi:10.1371/journal.pntd.0002816
- 339 17. Thakur CP, Kumar A, Mitra DK, Roy A, Sinha AK, Ranjan A. Improving outcome of
340 treatment of Kala-Azar by supplementation of amphotericin B with physiologic saline
341 and potassium chloride. *Am J Trop Med Hyg.* 2010;83(5):1040-1043.
342 doi:10.4269/ajtmh.2010.10-0255
- 343 18. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B
344 deoxycholate treatment of visceral leishmaniasis with newer modes of administration
345 and precautions: A study of 938 cases. *Trans R Soc Trop Med Hyg.* 1999;93(3):319-
346 323. doi:10.1016/S0035-9203(99)90037-8
- 347 19. Moore E, O'Flaherty D, Heuvelmans H, et al. Comparison of generic and proprietary
348 sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. *Bull*
349 *World Health Organ.* 2001;79(5):388-393. doi:10.1590/S0042-96862001000500004
- 350 20. Mbui J, Olobo J, Omollo R, et al. Pharmacokinetics, safety and efficacy of an allometric
351 miltefosine regimen for the treatment of visceral leishmaniasis in Eastern African
352 children: an open-label, phase-II clinical trial. *Clin Infect Dis.* Published online 2018.

- 353 doi:10.1093/cid/ciy747
- 354 21. Rees PH, Kager PA, Welde BT, Hockmeyer WT. The response of Kenyan kala-azar to
355 treatment with sodium stibogluconate. *Am J Trop Med Hyg.* 1984;33(3):357-361.
356 doi:10.4269/ajtmh.1984.33.357
- 357 22. Adam GK, Abdulla MA, Ahmed AA, Adam I. Maternal and perinatal outcomes of
358 visceral leishmaniasis (kala-azar) treated with sodium stibogluconate in eastern
359 Sudan. *Int J Gynecol Obstet.* 2009;107(3):208-210. doi:10.1016/j.ijgo.2009.08.002
- 360 23. Thakur CP, Sinha GP, Sharma V, Pandey AK, Sinha PK, Barat D. Efficacy of
361 amphotericin B in multi-drug resistant kala-azar in children in first decade of life.
362 *Indian J Pediatr.* 1993;60(1):29-36. doi:10.1007/BF02860503
- 363 24. Haider NA, Diab A-BL, EL-Sheikh AM. Visceral Leishmaniasis in children in the Yemen.
364 *Saudi Med J.* 1990;11(2):99-104.
- 365 25. Berhe N, Wolday D, Hailu A, et al. HIV viral load and response to antileishmanial
366 chemotherapy in co-infected patients. *AIDS.* 1999;13(14):1921-1925.
367 doi:10.1097/00002030-199910010-00015
- 368 26. Lackritz EM, Campbell C, Ruebush II T, et al. Effect of blood transfusion on survival
369 among children in a Kenyan hospital. *Lancet.* 1992;340:524-528.
- 370 27. Hebert PC, Wells G, Blajchman MA, et al. A Multicenter, Randomized, Controlled
371 Clinical Trial of Transfusion Requirements in Critical Care. *J Urol.* 1999;162(1):280-
372 280. doi:10.1097/00005392-199907000-00110
- 373 28. Carson JL, Sieber F, Cook DR, et al. Liberal versus restrictive blood transfusion
374 strategy: 3-year survival and cause of death results from the FOCUS randomised

- 375 controlled trial. *Lancet*. 2015;385(9974):1183-1189. doi:10.1016/S0140-
- 376 6736(14)62286-8
- 377 29. Maitland K, Ohuma EO, Mpoya A, Uyoga S, Hassall O, Williams TN. Informing
- 378 thresholds for paediatric transfusion in Africa: The need for a trial. *Wellcome Open*
- 379 *Res*. 2019;4:1-25. doi:10.12688/wellcomeopenres.15003.2
- 380 30. Kansagara D, Dyer E, Englander H, Fu R, Freeman M, Kagen D. Treatment of anemia in
- 381 patients with heart disease: A systematic review. *Ann Intern Med*. 2013;159(11):746-
- 382 757. doi:10.7326/0003-4819-159-11-201312030-00007
- 383 31. WHO. *Pocket Book of Hospital Care for Children: Guidelines for the Management of*
- 384 *Common Childhood Illnesses - 2nd Ed.*; 2013.
- 385 32. Retter A, Wyncoll D, Pearse R, et al. Guidelines on the management of anaemia and
- 386 red cell transfusion in adult critically ill patients. *Br J Haematol*. 2013;160(4):445-464.
- 387 doi:10.1111/bjh.12143
- 388 33. Vincent JL. Which carries the biggest risk: Anaemia or blood transfusion? *Transfus Clin*
- 389 *Biol*. 2015;22(3):148-150. doi:10.1016/j.tracli.2015.05.001
- 390 34. Lucy Paintain, Hererro M, Aggarwal V, et al. Cross-sectional surveys in Bangladesh,
- 391 India, Ethiopia & Sudan: understanding treatment seeking & household economic
- 392 burden for VL patients. In: *WorldLeish Congress, 16-20 May 2017, Toledo, Spain.* ;
- 393 2017.
- 394 35. Pekelharing JE, Gatluak F, Harrison T, Maldonado F, Siddiqui MR, Ritmeijer K.
- 395 Outcomes of visceral leishmaniasis in pregnancy: A retrospective cohort study from
- 396 South Sudan. *PLoS Negl Trop Dis*. 2020;14(1):e0007992.

- 397 doi:<https://dx.doi.org/10.1371/journal.pntd.0007992>
- 398 36. Delaney M, Wendel S, Bercovitz RS, et al. Transfusion reactions: prevention,
399 diagnosis, and treatment. *Lancet*. 2016;388(10061):2825-2836. doi:10.1016/S0140-
400 6736(15)01313-6
- 401 37. Burchenal JH, Bowers RF, Haedicke TA. Visceral Leishmaniasis Complicated by Severe
402 Anemia—Improvement Following Splenectomy. *Am J Trop Med Hyg*. 1947;27(6):699-
403 709. doi:<https://doi.org/10.4269/ajtmh.1947.s1-27.699>
- 404 38. Cachia EA, Fenech FF. A review of kala-azar in Malta from 1947 to 1962. *Trans R Soc*
405 *Trop Med Hyg*. 1964;58(3):234-241. doi:10.1016/0035-9203(64)90035-5
- 406 39. Grech V, Mizzi J, Mangion M, Vella C. Visceral leishmaniasis in Malta - An 18 year
407 paediatric, population based study. *Arch Dis Child*. 2000;82(5):381-385.
408 doi:10.1136/adc.82.5.381
- 409 40. Thakur CP, Ahmed S. Observations on amphotericin B treatment of kala-azar given in
410 a rural set up in Bihar, India. *Indian J Med Res*. 2001;113(JAN.):14-18.
- 411 41. Ekram MR, Amin MR, Hasan MJ, et al. Efficacy and safety of single-dose liposomal
412 amphotericin B in patients with visceral leishmaniasis in Bangladesh: a real-life
413 experience. *J Parasit Dis*. 2021;45(4):903-911. doi:10.1007/s12639-021-01379-w
- 414 42. Thakur CP, Kumar M, Kumar P, Mishra BN, Pandey AK. Rationalisation of regimens of
415 treatment of kala-azar with sodium stibogluconate in India: A randomised study. *Br*
416 *Med J (Clin Res Ed)*. 1988;296(6636):1557-1561. doi:10.1136/bmj.296.6636.1557
- 417 43. Thakur CP, Kumar M, Pandey AK. Comparisons of regimens of treatment of antimony-
418 resistant Kala-Azar patients: A randomized study. *Am J Trop Med Hyg*. 1991;45(4).

- 419 44. Dietze R, Milan E, Berman J, Groggl M, et al. Treatment of Brazilian kala-azar with a
420 short course of amphocil (amphotericin B cholesterol dispersion). *Clin Infect Dis*.
421 1993;17(6):981-986.
- 422 45. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B
423 deoxycholate treatment of visceral leishmaniasis with newer modes of administration
424 and precautions: A study of 938 cases. *Trans R Soc Trop Med Hyg*. 1999;93(3):319-
425 323. doi:10.1016/S0035-9203(99)90037-8
- 426 46. Moore E, O'Flaherty D, Heuvelmans H, et al. Comparison of generic and proprietary
427 sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. *Bull*
428 *World Health Organ*. 2001;79(5):388-393.
- 429 47. Mueller Y, Nguimfack A, Cavailler P, et al. Safety and effectiveness of amphotericin B
430 deoxycholate for the treatment of visceral leishmaniasis in Uganda. *Ann Trop Med*
431 *Parasitol*. 2008;102(1):11-19. doi:10.1179/136485908X252142
- 432 48. Das VNR, Siddiqui NA, Pandey K, et al. A controlled, randomized nonblinded clinical
433 trial to assess the efficacy of amphotericin B deoxycholate as compared to
434 pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases
435 in Bihar, India. *Ther Clin Risk Manag*. 2009;5(1):117-124. doi:10.2147/TCRM.S3581
436

437 **Table 1: Haematological parameters considered for defining inclusion/exclusion criteria for patient enrolment**

Haematological parameters	Number of studies (number of patients)	% (n=160)
Minimum haemoglobin concentration		
>3 g/dL	8 (n=1,804)	5.0%
>3 to <=5 g/dL	38 (n=11,452)	23.8%
>5 to <=7 g/dL	22 (n=2,644)	13.8%
Unclear	92 (n=19,863)	57.5%
Prothrombin time (above control values)		
>4 seconds	9 (n=1,277)	5.6%
>5 seconds	14 (n=5,599)	8.8%
>15 seconds	2 (n=631)	1.3%
>20 seconds	1 (n=89)	0.6%
Prothrombin activity <40%	1 (n=57)	0.6%
INR >2	1 (n=378)	0.6%
Unclear	132 (27,732)	82.5%
Minimum platelets concentration		
>4,000/ μ L	1 (n=30)	0.6%
>5,000/ μ L	1 (n=60)	0.6%
>20,000/ μ L	1 (n=378)	0.6%
>30,000/ μ L	2 (n=38)	1.3%
>40,000/ μ L	22 (n=7,432)	13.8%
>50,000/ μ L	19 (2,681)	11.9%
>60,000/ μ L	1 (n=230)	0.6%
>75,000/ μ L	1 (n=120)	0.6%
>80,000/ μ L	4 (n=50)	2.5%

	Unclear	108 (n=24,274)	67.5%
Minimum WBC count			
	<750/ μ L	1 (n=412)	0.6%
	<1,000/ μ L	18 (n=7,086)	11.3%
	<2,000/ μ L	8 (n=756)	5.0%
	<1,000/mL	1 (n=30)	0.6%
	<2,000/nL	1 (n=39)	0.6%
	granulocytes <1,000/ μ l	18 (n=3,636)	11.3%
	granulocytes <2,000/ μ l	1 (n=45)	0.6%
	Unclear	112 (n=23,763)	70.0%

438 INR= International normalisation ratio

439 **Table 2: Description of transfusion in clinical studies of VL indexed in the IDDO living systematic review library**

Author-year	Country	Drug regimen	Total enrolled	Number of transfusions	Transfusion rules	Transfused product	Description	Number of Patients requiring transfusion at baseline	Transfusion during treatment /follow-up
Rees-1984 ²¹	Kenya	SSG	16	1	Unclear if there were any specific rules (the transfused patient had Hb measurement of 3.2 g/dL)	Blood	In one pregnant patient with a haemoglobin of 3.2 g/dl, 2 pints of blood were given concomitantly with the commencement of SSG	-	Transfused during treatment; unclear number of patients
Thakur-1984 ¹⁴	India	SSG	750	4	4 g/dL +poor health OR haemorrhage	Blood	If Hb was below 4.0 g/dL and the general condition of the patient was poor, a blood transfusion was given. Blood transfusions were given to all cases with haemorrhage. Four cases of cancrum oris were encountered in the early phase of the epidemic when drugs were scarce. With specific treatment, general management with blood transfusion and oral protein supplements and crystalline penicillin, cancrum oris improved.	-	-
Thakur-1988 ⁴²	India	SSG	371	0	Unclear	No transfusion	As our patients were selected so that they did not have a haemoglobin concentration of less than 3 g/dL no blood transfusion was required for any patient	0	0
Thakur-1991 ⁴³	India	Pentamidine; Pentamidine + SSG	312	Unclear	3 g/dL	Blood	Patients whose haemoglobin level was less than 3 g/dL were given a blood transfusion, and when the haemoglobin level improved beyond 3 g/dL, they were included in the trial	Transfused at baseline; Unclear number of patients	-
Dietze-1993 ⁴⁴	Brazil	ABCD	20	Unclear	Unclear	Red cells	Some patients were administered transfusions of red blood cells during therapy	-	Transfused during treatment; unclear number of patients


Thakur-1993 ²³	India	Amphotericin B	50	4	4 g/dL + pre-existing hemorrhagic problems	Blood	Patients were given blood transfusions if they had haemoglobin below 4 g/dL, or had any hemorrhagic problems like epistaxis. Epistaxis occurred in 4 patients and it was treated with blood transfusions (Table 1 of the publication indicates transfusions occurred before treatment as no epistaxis occurred)	4	0
Berhe-1999 ²⁵	Ethiopia	PA	23	Unclear	severe anaemia	Blood	Blood transfusion was given to patients with severe anaemia and the post-transfusion haemoglobin value among the two groups was not different	-	-
Thakur-1999 ⁴⁵	India	AMBd	938	56	5 g/dL	Blood	The initial precaution taken was that patients whose haemoglobin level was below 5 g/dL were given blood transfusion first and only when the haemoglobin reached 5 g/dL was treatment for visceral leishmaniasis started. Blood transfusion was required in 54 (6%) patients before start of treatment. Anaemia improved with treatment but in 2 patients, haemoglobin dropped after treatment and they required blood transfusion	54	2
Moore-2001 ⁴⁶	Kenya	SSG	102	43	anaemia	Blood	Blood transfusions were available for anaemic patients. Patients required transfusions during and after treatment; as described in Table 2 of the manuscript ⁴⁶ .	-	43
Haidar-2001 ²⁴	Yemen	SSG	32	24	Unclear	Blood	Blood transfusions were required for 24 patients (73%)	-	-
Mueller-2008 ⁴⁷	Uganda	AMBd; PA	371	Unclear	severe anaemia	Blood	Blood transfusions for severe anaemia were given, if necessary	-	-
Das-2009 ⁴⁸	India	AMBd; Pentamidine	82	Unclear	6 g/dL	Blood	In cases of VL, who had severe anaemia (Hb < 6 g/dl), before excluding such patients from the study, an effort was undertaken to increase their haemoglobin level by giving fresh blood transfusion as required	Transfused at baseline; Unclear number of patients	-
Adam-2009 ²²	Sudan	SSG	42	42	severe anaemia	Blood	All 42 patients received blood transfusions for severe anaemia	-	-
Thakur-2010 ¹⁷	India	Amphotericin B	230	Unclear	5 g/dL	Whole blood/platelets	If patients had haemoglobin levels < 5 g/dL or a thrombocyte count < 65,000 cells/ μ L, whole blood transfusions or platelet transfusions were given, respectively. If these two parameters reached acceptable levels, only then were the patients included in the trial	Transfused at baseline; Unclear number of patients	-

Cota-2014 ¹⁶ (HIV negative)	Brazil	PA; AMBd; L-AmB	46	19*	Measured Hb/platelets/INR + clinical instability/bleeding	Red cells or plasma or platelets	In this study, all types of blood products were accounted for between baseline and the end of hospitalisation for VL treatment. Specific transfusion rules: platelets: <20,000 + active bleeding or below 50,000 before performing invasive procedures; red cells: severe anaemia or Hb < 8 g/dL + clinical instability; plasma: INR > 1,5 + active bleeding	-	-
Cota-2014 ¹⁶ (HIV positive)	Brazil	PA; AMBd; L-AmB	44	23*	Measured Hb/platelets/INR + clinical instability/bleeding	Red cells or plasma or platelets	In this study, all types of blood products were accounted for between baseline and the end of hospitalisation for VL treatment. Specific transfusion rules: platelets: <20,000 + active bleeding or below 50,000 before performing invasive procedures; red cells: severe anaemia or Hb < 8 g/dL + clinical instability; plasma: INR > 1,5 + active bleeding	-	-
Mbui-2018 ²⁰	Kenya, Uganda	Miltefosine	30	1	Unclear	Unclear	The first had a case of “transfusion reaction” that was considered an important medical event by the investigator, occurring on day 203 after the treatment start	-	1

440 Three trials that reported provision for haematological profile correction prior to patients enrolment without describing if any transfusions were carried out; these studies
441 are not included in this table^{15,40,41}.

442 Hb= haemoglobin; SSG = Sodium stibogluconate; PA = Pentavalent antimony; AMB = Amphotericin B; AMBd = Amphotericin B deoxycholate; ABCD= Amphotericin B
443 colloidal dispersion

444



445

446 **Figure 1: Proportion of patients undergoing transfusion in 10 studies that clearly reported the transfusion status**

447 **Box 1: Transfusion parameters**

Item	Description
Haematological parameters	Rules used for indicating transfusion
	Haemoglobin (or haematocrit) level used for indicating transfusion
	Information regarding blood/blood products transfused: whole blood, plasma, platelets
	Units of transfused blood/blood products/transfusion volume
	Time-point of transfusion: before treatment, during treatment (in days) or during the follow-up phase (in days or weeks)
	Reason for transfusion: severe anaemia, acute blood loss, epistaxis/haemorrhage/splenic bleeding
	Minimum haemoglobin concentration required for patient enrolment into a study
	Definition of anaemia/severe anaemia
Distinction between patients and episodes	
	Number of patients who required transfusion
	Total number of episodes of transfusion
Therapeutic outcomes	
	Reports of transfusion reactions, including the nature of the transfusion reaction (if any)
	Therapeutic outcomes stratified by transfusion status for each drug regimen

448